

Product Datasheet

Rodatristat ethyl

Catalog No. **BP-01919** · CAS **1673571-51-1** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-04**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Tryptophan Hydroxylase; 5-HT Receptor	Research area Cardiovascular Disease
--	--

Molecular formula **C₂₉H₃₁ClF₃N₅O₃**

Molecular weight **590.0360**

STRUCTURE



DESCRIPTION

Rodatristat ethyl (KAR5585) is a first-in-class oral tryptophan hydroxylase 1 (TPH1) Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of 5-HT and significantly reduces pulmonary arterial hypertension (PAH).

BIOLOGICAL ACTIVITY

In Vivo

Rodatristat ethyl (100 or 200 mg/kg; oral administration; once daily; for 28 days; male Sprague-Dawley rats) treatment decreases erum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduces pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats with monocrotaline (MCT).

SOLUBILITY

Soluble in DMSO : 100 mg/mL

REFERENCES

- [1]. Aiello RJ, et al. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Modelsof Pulmonary Hypertension. J Pharmacol Exp Ther. 2017 Feb;360(2):267-279.
- [2]. Alice Melão, MSc. Early Results on Rodatristat Ethyl Support Launch of Phase 2 Trial in PAH Patients. FEBRUARY 4, 2019.